(CNN)As more places across the US offer people a chance to shop or dine inside, the issue of whether to wear a mask has again become a flashpoint.
Japan has completely lifted its nationwide state of emergency.
The country's prime minister, Shinzo Abe, announced Monday that officials have loosened the coronavirus restrictions in the last five of the country's 47 prefectures: Tokyo and its surrounding regions, as well as the northern island of Hokkaido.
Just 7.3% of Stockholm’s inhabitants had developed Covid-19 antibodies by the end of April, according to a study, raising concerns that the country’s light-touch approach to the coronavirus may not be helping it build up broad immunity.
The coronavirus may still be spreading at epidemic rates in 24 states, particularly in the South and Midwest, according to new research that highlights the risk of a second wave of infections in places that reopen too quickly or without sufficient precautions.
The drug US President Donald Trump said he was taking to ward off Covid-19 actually increases the risk of patients with the disease dying from it, a study in the Lancet has found.
The study said there were no benefits to treating patients with the anti-malarial drug hydroxychloroquine.
Mr Trump said he was taking the drug despite public health officials warning that it could cause heart problems.
The president has repeatedly promoted the drug, against medical advice.
China reported no new symptomatic coronavirus cases on Saturday, for the first time since the beginning of the outbreak in December.
There were 28 new asymptomatic cases, which are counted separately, the National Health Commission (NHC) said.
The United States has secured almost a third of the first one billion doses planned for AstraZeneca’s experimental COVID-19 vaccine by pledging up to $1.2 billion, as world powers scramble for medicines to get their economies back to work.
The vaccine, previously known as ChAdOx1 nCoV-19 and now as AZD1222, was developed by the University of Oxford and licensed to AstraZeneca. Immunity to the new coronavirus is uncertain and so the use of vaccines is unclear.
The United States will pump up to $1.2 billion into developing AstraZeneca’s potential COVID-19 vaccine and said on Thursday it would order 300 million doses, as the White House seeks solutions to the coronavirus pandemic.
The commitment provides for a possible U.S.-based clinical trial this summer involving 30,000 volunteers and adds fuel to the British drugmaker’s efforts to develop a vaccine for the disease, one of around 100 which are under way worldwide.
People who recover from COVID-19 but test positive for the virus again days or weeks later are not shedding viral particles and are not infectious, according to data released Tuesday by the Korea Centers for Disease Control and Prevention.
